A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled,Single and Multiple Ascending Intravenous Dose Study toAssess the Safety, Tolerability, Pharmacokinetics of VGL101 in HealthyAdults

Phase 1

Completed

• Conditions: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia; Neurological - Other neurological disorders

• Registration Number: ACTRN12622000933752
• Lead Sponsor: Vigil Neuroscience, Inc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-06-30
• Study Completion: 2023-08-01
• Last Update Posted: 5 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Males and females between 18 to 55 years of age, inclusive, at the Screening Visit.

Exclusion Criteria

Participant has any concurrent disease or condition that, in the opinion of the PI, would
make the participant unsuitable for participation in the clinical study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified